HSE - PCRS

Application Details

HSE Application ID

HSE100106

HTA Number

26020

HTA Link

https://www.ncpe.ie/dostarlimab-jemperli-hta-id-26020/

Drug

dostarlimab

Brand

Jemperli®

Applicant

GlaxoSmithKline Limited

Indication Applied For

Dostarlimab in combination with carboplatin and paclitaxel indicated for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.  
This application focuses on a subgroup of patients with recurrent or advanced deoxyribonucleic acid (DNA) mismatch repair proficient (MMRp) or microsatellite-stable (MSS) EC who are candidates for systemic therapy.

Application Date

07/05/2026

Marketing Authorisation Date

15/01/2025

Application Status

Awaiting Proposal from Applicant

09/07/2026

Applicant Meeting Held with CPU

09/07/2026

Full Health Technology Assessment Commissioned by HSE

22/05/2026

Rapid Review Completed

21/05/2026

Pricing and Reimbursement Application Complete

07/05/2026

Rapid Review Commissioned

06/05/2026

New Search